Follicum AB (“Follicum” or the “company”) today announced that more than 50% of the patients have been recruited in the ongoing, clinical phase IIa study with FOL-005. The study involves 200 male patients with hair loss who are treated daily for four months with a newly developed topical formulation of FOL-005 or placebo. The study […]
Follicum AB (“Follicum”) has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance of the US patent application 16/666,960. The patent application covers the company’s peptides and their use for treatment of diabetes and diabetes-associated complications. The application is directed to new peptides from the company’s two […]
Follicum AB (“Follicum” or the “company”) today announced that the clinical Phase IIa study with a cream-like formulation of FOL-005 will re-start, following a pause due to the Covid-19 pandemic. To increase the recruitment rate, a third study centre has been contracted. The study comprises approximately 200 male patients with hair loss who are treated […]
Follicum AB (“Follicum” or the “company”) announces that the company has filed an international patent application (PCT) covering the formulation of FOL-005 developed by the company. The patent application is based on new experimental data that supports the use of the formulation for peptides other than FOL-005. The formulation of FOL-005 intended for topical application […]
Follicum AB (“Follicum”) announces that the company has today received a preliminary approval from the European Patent Office (EPO) of a patent application concerning the company’s new class of peptides that are being developed to treat diabetes. Follicum’s patent application with publication number EP 3 618 845 comprises new peptides and their use in the […]
Follicum AB (“Follicum” or “the company”) today announces that the company has decided to temporarily suspend the phase II study of the drug candidate FOL-005 recently initiated in Germany. This is due to government recommendations in Germany in light of the ongoing outbreak of COVID-19. The company intends to resume the recruitment of patients for […]
Follicum AB (“Follicum” or “the company”) today announces that the first group of patients have been treated in the new clinical phase IIa study with FOL-005. The study will include approximately 200 male patients with hair loss who are to be treated daily for 4 months with the new formulation of FOL-005 or placebo. The […]
Follicum (“Follicum” or “the Company”) today announces that the company’s grant application to Vinnova to study binding of FOL peptides to receptors on pancreatic cells has been approved. Follicum is the coordinator of the project, which also includes Lund University and SARomics Biostructures. Parts of the project involve advanced analysis work to be performed at […]
Follicum AB (“Follicum” or “the Company”) today announces that it has received approval from the German Medicines Agency (BfArM) and the German Ethics Committee to start a Phase IIa clinical study with a topical formulation of FOL-005 on patients with alopecia (hair loss). The trial will comprise about 200 patients who will be treated with […]
Follicum AB (“Follicum” or “the Company”) today announces that data from studies on human Langerhans islets have shown positive effects on insulin release in line with the previously reported results on beta cells isolated from animals. The studies were performed through two different collaborations, one with Lund University and one with InSphero, Switzerland and showed […]